Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070206 | Skin | cSCC | microtubule nucleation | 20/4864 | 35/18723 | 9.08e-05 | 8.48e-04 | 20 |
GO:009050421 | Skin | cSCC | epiboly | 20/4864 | 35/18723 | 9.08e-05 | 8.48e-04 | 20 |
GO:00310234 | Skin | cSCC | microtubule organizing center organization | 58/4864 | 143/18723 | 9.47e-05 | 8.83e-04 | 58 |
GO:000716024 | Skin | cSCC | cell-matrix adhesion | 85/4864 | 233/18723 | 2.43e-04 | 1.98e-03 | 85 |
GO:00400012 | Skin | cSCC | establishment of mitotic spindle localization | 19/4864 | 35/18723 | 3.37e-04 | 2.67e-03 | 19 |
GO:005101729 | Skin | cSCC | actin filament bundle assembly | 60/4864 | 157/18723 | 4.86e-04 | 3.66e-03 | 60 |
GO:00516534 | Skin | cSCC | spindle localization | 26/4864 | 56/18723 | 7.59e-04 | 5.27e-03 | 26 |
GO:004678513 | Skin | cSCC | microtubule polymerization | 35/4864 | 83/18723 | 9.52e-04 | 6.47e-03 | 35 |
GO:006157229 | Skin | cSCC | actin filament bundle organization | 60/4864 | 161/18723 | 1.02e-03 | 6.86e-03 | 60 |
GO:000201114 | Skin | cSCC | morphogenesis of an epithelial sheet | 26/4864 | 57/18723 | 1.05e-03 | 7.06e-03 | 26 |
GO:00512931 | Skin | cSCC | establishment of spindle localization | 23/4864 | 51/18723 | 2.41e-03 | 1.38e-02 | 23 |
GO:003288612 | Skin | cSCC | regulation of microtubule-based process | 82/4864 | 240/18723 | 2.82e-03 | 1.58e-02 | 82 |
GO:190290425 | Skin | cSCC | negative regulation of supramolecular fiber organization | 59/4864 | 167/18723 | 4.56e-03 | 2.33e-02 | 59 |
GO:001063125 | Skin | cSCC | epithelial cell migration | 115/4864 | 357/18723 | 4.64e-03 | 2.37e-02 | 115 |
GO:003110911 | Skin | cSCC | microtubule polymerization or depolymerization | 45/4864 | 122/18723 | 5.05e-03 | 2.56e-02 | 45 |
GO:004362411 | Skin | cSCC | cellular protein complex disassembly | 49/4864 | 136/18723 | 6.00e-03 | 2.95e-02 | 49 |
GO:009013225 | Skin | cSCC | epithelium migration | 115/4864 | 360/18723 | 6.20e-03 | 3.04e-02 | 115 |
GO:004599521 | Skin | cSCC | regulation of embryonic development | 26/4864 | 64/18723 | 7.34e-03 | 3.47e-02 | 26 |
GO:000716224 | Skin | cSCC | negative regulation of cell adhesion | 98/4864 | 303/18723 | 7.45e-03 | 3.50e-02 | 98 |
GO:0032231111 | Skin | cSCC | regulation of actin filament bundle assembly | 39/4864 | 105/18723 | 7.56e-03 | 3.53e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLASP2 | SNV | Missense_Mutation | | c.1111N>A | p.Asp371Asn | p.D371N | | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
CLASP2 | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | | protein_coding | tolerated(0.23) | benign(0.234) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | | c.1355T>C | p.Val452Ala | p.V452A | | protein_coding | tolerated(0.06) | probably_damaging(0.954) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | rs554149266 | c.1343N>A | p.Arg448Gln | p.R448Q | | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.3842G>T | p.Gly1281Val | p.G1281V | | protein_coding | deleterious(0.03) | possibly_damaging(0.531) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CLASP2 | SNV | Missense_Mutation | novel | c.179N>A | p.Gly60Glu | p.G60E | | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2793N>A | p.Met931Ile | p.M931I | | protein_coding | deleterious(0.01) | benign(0.233) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2897C>G | p.Ser966Cys | p.S966C | | protein_coding | deleterious(0.03) | possibly_damaging(0.54) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.2311N>G | p.Leu771Val | p.L771V | | protein_coding | tolerated(0.17) | possibly_damaging(0.875) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CLASP2 | insertion | Nonsense_Mutation | novel | c.2873_2874insCTAGGGATGAGGCCTACATGACCATGGTG | p.Met958IlefsTer2 | p.M958Ifs*2 | | protein_coding | | | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |